DGX · CIK 1022079
What Quest Diagnostics Incorporated told the SEC could break it.
Quest Diagnostics' disclosures revolve around who pays for its tests. Health plans are central — about 40% of its diagnostic-services revenue and nearly half its clinical testing volume — and its five largest health plans together were roughly 20% of consolidated 2025 net revenue (no single plan at 10%), a concentration heightened by ongoing health-plan consolidation and narrowing networks. The rest of its register is government healthcare policy that reshapes its payer mix and reimbursement: the Inflation Reduction Act's enhanced ACA Premium Tax Credits expired at the end of 2025, which could shrink individual-exchange enrollment, and pending OBBBA Medicaid implementation guidance — effective in 2027 and 2028 — could shift patient populations and reimbursement for the roughly 8% of revenue tied to Medicaid.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- ACA enhanced Premium Tax Credit expirationmedium
The IRA's enhanced ACA Premium Tax Credits expired at the end of 2025; expiration could shrink Individual Public Exchange enrollment and shift payer mix/utilization.
“In addition, the enhanced Premium Tax Credits (“PTC”) that were part of the Inflation Reduction Act of 2022, which have helped drive an increase in Individual Public Exchange enrollment, expired at the end of 2025 and such expiration could also have an impact on patient populations and result in shifts among payer types and utilization.”
SEC filing →As of 2026 - OBBBA Medicaid implementationmedium
Medicaid and managed Medicaid were ~8% of 2025 revenues; pending federal/state OBBBA implementation guidance (effective 2027–2028) could shift patient populations and reimbursement.
“Additional federal and state guidance is expected to be issued in order to implement the various provisions of the OBBBA, many of which have effective dates in 2027 and 2028.”
SEC filing →As of 2026
Customer concentration
- health plan payers (top 5 = ~20% of net revenues)medium
Health plans are ~40% of diagnostic-services net revenues and nearly half of clinical testing volume; the five largest health plans were ~20% of consolidated net revenues in 2025 (no single plan ≥10%), amid health-plan consolidation and narrowing networks.
“Reimbursement from our five largest health plans totaled approximately 20%, and no one health plan accounted for 10%, of our consolidated net revenues in 2025. Health plans typically negotiate directly or indirectly with a number of diagnostic information services providers, and represent nearly one-half of our total clinical testing volume and approximately 40% of our net revenues from diagnostic information services.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch